A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors

PURPOSE: To evaluate the safety, tolerability, pharmacokinetics, and efficacy of the intravenously administered pan-PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors. METHODS: A Phase I open-label study in Japanese patients with advanced or refractory solid tumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Doi, Toshihiko, Fuse, Nozomu, Yoshino, Takayuki, Kojima, Takashi, Bando, Hideaki, Miyamoto, Hideaki, Kaneko, Masato, Osada, Motonobu, Ohtsu, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225172/
https://www.ncbi.nlm.nih.gov/pubmed/27915408
http://dx.doi.org/10.1007/s00280-016-3198-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225172/
https://www.ncbi.nlm.nih.gov/pubmed/27915408
http://dx.doi.org/10.1007/s00280-016-3198-0

Ejemplares similares